Skip to main content

Table 1 Clinicalpathologic features of breast cancer patients

From: ICOS gene polymorphisms are associated with sporadic breast cancer: a case-control study

Feature

Study cohort

Validation cohort

 

Case no (%)

Case no (%)

Tumor type

  

   IDC

523(85.88)

528(85.30)

   MC

7(1.15)

6(0.97)

   Intraductal carcinoma

40(6.57)

45(7.27)

   Mucinous adenocarcinoma

14(2.30)

13(2.10)

   Others

25(4.11)

27(4.36)

Tumor size(cm)

  

   TZ ≤ 2

210(34.48)

200(32.31)

   2 < TZ ≤ 5

277(45.48)

289(46.69)

   TZ > 5

29(4.76)

37(5.98)

   Unknown

93(15.27)

93(15.02)

LN involvement

  

   Positive

263(43.19)

278(44.91)

   Negative

334(54.84)

333(53.80)

   Unknown

12(1.97)

8(1.29)

ER

  

   Positive

313(51.40)

361(58.32)

   Negative

208(34.15)

207(33.44)

   Unknown

88(14.45)

51(8.24)

PR

  

   Positive

382(62.73)

345(55.74)

   Negative

134(22.00)

223(36.03)

   Unknown

93(15.27)

51(8.24)

P53

  

   Positive

153(25.12)

144(23.26)

   Negative

353(57.96)

420(67.85)

   Unknown

103(16.91)

55(8.89)

C-erbB-2

  

   Positive

198(32.51)

187(30.21)

   Negative

317(52.05)

379(61.23)

   Unknown

94(15.44)

53(8.56)

  1. Abbreviations: IDC = infiltrative ductal carcinoma; MC = medullary carcinoma; LN = lymph node; TZ = tumor size; ER = estrogen receptor; PR = progesterone receptor